Roche: EU OKs Tecentriq for metastatic lung cancer
(CercleFinance.com) - The European Commission has approved Roche immunotherapy Tecentriq, in combination with Avastin and chemotherapy, for the initial treatment of people with a specific type of metastatic lung cancer.
The EU's approval was granted for metastatic non-squamous non-small cell lung cancer, offering a new treatment option for EGFR mutant or ALK-positive patients after failure of appropriate targeted therapies.
This approval is based on results from a Phase III study, which showed that Tecentriq, in combination with Avastin and chemotherapy, helped people live significantly longer, giving a median overall survival of 20 months.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The EU's approval was granted for metastatic non-squamous non-small cell lung cancer, offering a new treatment option for EGFR mutant or ALK-positive patients after failure of appropriate targeted therapies.
This approval is based on results from a Phase III study, which showed that Tecentriq, in combination with Avastin and chemotherapy, helped people live significantly longer, giving a median overall survival of 20 months.
Copyright (c) 2019 CercleFinance.com. All rights reserved.